Abstract 68P
Background
Luminal A (ER+/ HER2-low) is the most common breast cancer subtype and hormonal therapy is the preferred first-line treatment. However, most patients (>50%) develop resistance, leading to disease recurrence and limited clinical benefit, even with the addition of a combination regimen. Therefore, treatment optimization is required urgently. Furthermore, studies have indicated that the tumours with low HER2 and ER levels evade ER blockade via the upregulation of EGFR/HER2 signalling. Therefore, this study will aim to assess the effects of anti-HER2 in combination with hormone treatment in ER+/HER2-low breast cancer.
Methods
A panel of patient-derived organoids ( n=31) was successfully established and characterized using immunohistochemical and confocal imaging. Through the drug sensitivity test, the drug combination efficacy of the anti-HER2 drug (neratinib), hormone treatment (fulvestrant), and CDK4/6 inhibitor (palbociclib) was tested in HER2-low breast cancer patient-derived organoids. The underlying molecular mechanisms were investigated using immunofluorescence, western blot analysis, immunohistochemical staining, and cell cycle analysis.
Results
We found that neratinib combined with palbociclib and or fulvestrant showed better efficacy than palbociclib and fulvestrant combination in HER2-low breast cancer, resulting in the deactivation of HER2-EGFR signalling pathway, decreased transcriptional activation of ER and cycle proteins. Furthermore, the dual or triple combination of neratinib, palbociclib, and fulvestrant could decrease the nuclear translocation of ER. This may be the underlying mechanism by which the addition of palbociclib and/or fulvestrant to neratinib was more beneficial than the combination of palbociclib plus fulvestrant.
Conclusions
Our study provides the rationale for combining neratinib with fulvestrant and or palbociclib for the treatment of ER+/HER2-low breast cancer and indicates that the dual or triple combination treatment may be a better strategy to overcome resistance to hormone treatment. Moreover, future translational research will investigate the potential biomarkers indicating the responsiveness to the treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Puma biotechnology.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract